189. The Surprising Biomarker That’s Changing How Researchers Understand T1D

Have you ever wondered: What if, in those early days after diagnosis, there was something you could do to help protect the insulin your body still makes? In this episode, we’re exploring exactly that. I'm joined by Ulf Hannelius, CEO of Diamyd Medical, to talk about a therapy that could be a game-changer for people newly diagnosed with type 1 diabetes. It's called GAD therapy, and it's currently being studied in the DIAGNODE-3 clinical trial. We dig into the science behind this investigational treatment and the hope it offers for preserving the body’s remaining insulin production. Ulf not only explains the research in simple terms, but also shares his vision for the future of T1D. We know how overwhelming diabetes research can feel, but this is one conversation everyone in the T1D community should hear, especially if you or someone you love is facing a new diagnosis.Quick Takeaways:The latest research aiming to protect insulin production after a type 1 diabetes diagnosisA clear breakdown of Diamyd Medical’s GAD therapy and the DIAGNODE-3 trial — what it is, who it's for, and why it offers hope for the future of T1DWhat’s actually happening inside the body of someone newly diagnosed with type 1 diabetesDefining T1D terms you’ve probably heard but no one ever defines: Honeymoon phase, C-peptide, Stage 3 Type 1 Diabetes, Antigen-specific therapy, GAD65 + more What to do now: 📚Read more about the DIAGNODE-3 trial + see what else Diamyd has been up to recently here! ***Disclaimer: Interested in participating in the trial? You must be: Diagnosed with type 1 diabetes within the last 6 months. And between 12 - <29 years of age.📩SHARE this episode: Whether it’s with another T1D, a loved one, or even your endocrinologist.  📲Stay connected: Follow me @lauren_bongiorno and @riselyhealth on Instagram to stay in the loop when new episodes drop.💻Apply for coaching and talk to our team so you can reclaim the life you deserve.